© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Few innovations in Parkinson’s disease management have shifted patient outcomes like the arrival of entacapone. The 1990s marked a turning point: neurologists needed more than just levodopa’s punch; people wanted longer relief, steadier movement, and less of the cruel unpredictability levodopa sometimes brings. Plenty of Parkinson’s patients, after years on levodopa, end up on a rollercoaster—mobility surges then fades without warning. Drug developers turned to the biochemistry bench, targeting catechol-O-methyltransferase (COMT), an enzyme that quickly snatches away levodopa’s benefit. With entacapone entering European and U.S. markets, doctors gained a fresh tool. Levodopa lasted longer, and unpredictability faded. I watched a few relatives grapple with pill regimens that stretched into their daily routines, and the contrast before and after COMT inhibitors like entacapone struck home. The drug’s history isn’t just pages in a pharma almanac—it reshaped lived experience.
Entacapone often comes in orange-brown tablets, scored for easy division. You see it most in combinations with carbidopa and levodopa, often under brand names like Stalevo. As a selective, reversible inhibitor of the COMT enzyme, it stalls levodopa’s breakdown before reaching the brain. It’s not a dopamine source, it’s a boost for what’s already there. Whether as a lone agent or mixed in with the main therapy, its presence means more dopamine delivered where it counts. Wear-off, that frustrating loss of drug effect before the next dose, takes a back seat. The active ingredient remains unchanged in the main commercial versions—what shifts is pill strength, coloring agents, and coatings but not the core action.
On the chemistry front, entacapone sports the formula C14H15N3O5, molar mass just over 305 g/mol. Its yellow-orange appearance ties in with the nitro and carboxyl groups snug within its structure. At room temperature, it stands as a crystalline powder, stubbornly unyielding to water, but more cordial in organic solvents. That lack of water solubility guides both formulation decisions and considerations for absorption in the gut. Melting point holds around 140–142°C, and its stability under typical storage conditions means tablets or bulk powder don’t demand special tricks. Knowledge like this might seem dry, but in manufacturing, matching these properties with excipients and coatings becomes both art and necessity.
Each entacapone tablet in the pharmacy matches strict documentation from regulatory authorities. The most common strength, 200mg per tablet, lines up with rigorous standards—purity checks, impurity profiling, dissolution times, and uniformity in content. The package insert tells you what else mixes in: microcrystalline cellulose for tablet structure, magnesium stearate to keep everything smooth in production, and dyes for identification. FDA and EMA labeling details warnings—notably, the brownish-orange urine, a harmless effect but still alarming for the uninitiated. Pharmacokinetic details reveal a half-life under three hours; peak plasma levels within an hour after swallowing. Each of these written specs shields patient safety, locking down deviations from batch to batch. From a user perspective, reliability in dosing keeps both patient and physician confident in sticking to a routine.
The synthesis of entacapone uses principles familiar to many medicinal chemists. Starting with a substituted benzene ring, the path runs through nitration, carboxylation, then coupling to a 2-cyano-3,4-dihydroxy-5-nitrophenyl moiety—ruthless in its use of protection and deprotection steps to control side reactions. The last stage often depends on careful purification with column chromatography, stripping away residual catalysts and byproducts. Experienced chemists know the headaches of keeping yields high while minimizing costly waste. Scale-up from bench to industrial reactors adds layers—solvent recovery, waste treatment, and crude product washing all rear up as hurdles. While lab manuals and research articles spell out each reaction in chemical terms, not losing sight of waste streams and environmental impact sets apart a responsible operation.
Entacapone’s backbone lends itself to modifications, though most tweaks focus on COMT enzyme selectivity or pharmacokinetics. Some research teams explore esterifying the carboxylic acid to alter absorption or reduce gastrointestinal irritation. Others probe substitutions at the nitro group—hoping for a similar COMT block with less chance of side effects. In metabolite studies, the drug primarily undergoes isomerization and glucuronidation in the body, not oxidation or reduction, which is why patient bodies handle it with fewer unwanted surprises. These details matter in designing second-generation medications. Investors and research sponsors care about patents, but from a patient lens, new derivatives could mean shorter pill schedules, fewer side effects, and more predictable days.
While the pharmacy shelves in different regions sport names like Comtan or Stalevo, the underlying molecule doesn’t change. Sometimes, chemical suppliers sell it under the systematic name 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide, though it rarely shows up in actual therapeutic conversations. Health professionals and patients stick to trade names for clarity. The difference isn’t just labeling; insurance billing, formularies, and pharmacy software each recognize these variations, streamlining logistics for hospitals and clinics. On research benches, familiarity with synonyms keeps scientists from wasting time chasing duplicate compounds.
Laboratories and production sites handling entacapone don gloves, lab coats, and sometimes respirators during scale-up. Material safety data sheets warn of dust irritation, with the main occupational hazard being accidental ingestion or inhalation. Workers training in Good Manufacturing Practice (GMP) environments respect the importance of thorough cleaning after synthesis runs to prevent cross-contamination with other drugs. Disposal of waste—especially from solvent-heavy steps—demands both compliance and real diligence. Medical safety stands on different ground. Entacapone tends not to induce life-threatening reactions, but patients with severe liver dysfunction steer clear. Monitoring for neuroleptic malignant syndrome and dyskinesias becomes routine with long-term users, especially in the elderly. Emergency response plans in production plants, regular safety audits, and operator training back up a safer end product for everyone.
Levodopa-based therapy shapes lives for countless Parkinson’s patients. Entacapone’s role is firmly adjunct—reserved for patients whose treatment with carbidopa and levodopa alone yields rollercoasters of movement or “off” times. The reach is narrower than blockbuster blood pressure drugs, but incredibly impactful for those who need sustained motor function through the day. One pharmaceutical sales representative I spoke with years ago recalled how physicians described entacapone not as a miracle, but as an overdue improvement, cutting down on disabling unpredictability. Clinicians have explored its use in other conditions, such as restless leg syndrome and even tardive dyskinesia, though formal approval stays within Parkinson’s disease. This focus sharpens future research questions, nudging academics and clinicians to bridge real-world needs with molecular innovation.
Research doesn’t slow after a drug’s approval. CORE studies and post-marketing surveillance follow entacapone across continents, watching for rare side effects, drug interactions, or signs of waning benefit over years. New clinical questions emerge: Which patients see the greatest improvements? How does entacapone fare combined with deep brain stimulation or future gene therapies? Patient advocacy groups sometimes drive research with surveys on daily “off” time and functional independence, which shapes the priorities for both public and private funders. On the basic science side, medicinal chemists synthesize analogs trying to either extend action or reduce adverse effects. In the past decade, patent filings and conference abstracts hint at a shift toward even more selective COMT inhibitors, as molecular modeling grows more sophisticated. The spotlight remains on meaningful outcomes—more stable motor control, less involuntary movement, and, for families, fewer unpredictable care routines.
Toxicity assessments started on animal models before human trials began. Standard studies track everything—heart, liver, kidney, and neurologic safety. Dose-ranging tests help set safe upper limits for patients. Liver function tests stand front and center, as the main route of excretion puts burden on hepatic pathways. Regulatory authorities dig deep into long-term carcinogenicity and reproductive safety results before approving new indications. For the bedside clinician, practical reminders matter—warn about brown urine, watch for any shifts in liver enzymes, and monitor for hallucinations or confusion in those stepping up doses. Ongoing pharmacovigilance teams collect real-world safety data, so new risks never slide unnoticed. From a personal view, open and honest conversations between prescriber and patient about all possible risks demystify the process and foster trust.
Looking forward, entacapone’s legacy shapes the next generation of COMT inhibitors, push toward simpler regimens, and longer-acting drugs. Pharmaceutical sponsors eye new combination tablets, even exploring depot injections for steadier bloodstream levels without daily pills. With advances in brain imaging, some researchers hope to connect changes in dopamine availability with live behavioral feedback, opening new ways to measure real benefit. Drug resistance, subgroups with limited benefit, and cost-effectiveness questions all loom ahead. On the clinical front, some hope wearable movement sensors could fine-tune dosing—a fusion of digital health and pharmaceutical care. For the global Parkinson’s community, the measure of success will not be patent filings or sales numbers but tangible, everyday improvement in independence and dignity. The story of entacapone proves that listening to real patient struggles—and not just lab stats—guides medicine in the right direction.
Parkinson’s turns daily routines into challenges. Every handshake, meal, or walk to the store takes effort. I have seen what this means for friends and neighbors. One thing that’s clear: medication decisions carry real weight for folks facing tremors and stiffness. Everyone wants more good hours in their day.
Entacapone comes in as a partner for levodopa, the drug that offers many their best shot at steady movement. Alone, levodopa does its job for a while, but over time, the benefit starts to wear off sooner. People notice it: “On” periods shrink, and “off” times, when symptoms come right back, grow longer. Enter entacapone. Taken along with levodopa/carbidopa, it works on the body’s chemistry to help keep more levodopa available for the brain.
Entacapone works by blocking an enzyme called COMT. This enzyme breaks down levodopa before it reaches the brain. With COMT out of the picture, more levodopa gets where it’s needed, and its effects stick around a bit longer. In practice, that means fewer sudden drops in movement, and maybe a smoother day.
Every drug has tradeoffs. Entacapone brings some, too. Some people notice their urine turning orange—harmless, but surprising at first. Other, more important things to watch include diarrhea, confusion, or increased involuntary movements. Anyone thinking of this medicine should talk with their doctor about risks and whether it fits into their plan. From my reading and the people I’ve spoken with, regular check-ins and honest discussion make a real difference.
No two people with Parkinson’s have the same experience. Some medications work well for years, then lose steam or cause new issues. Adding entacapone offers another tool for families and doctors. It isn’t a cure, and not everyone will want or need it, but for some, it stretches the benefits of each levodopa dose a bit further.
Studies published by groups like the American Academy of Neurology show that combining entacapone with levodopa can reduce daily “off” time by almost an hour. That might sound small, until you’re the one waiting for your hands to work so you can hold a grandchild or drink coffee without spilling.
Parkinson’s comes with uncertainty, and every hour spent moving well means more time for the moments that matter. Entacapone brings hope for smoother days. More research is rolling out each year, and the ideal mix of medicines keeps changing. People living with Parkinson’s, their families, and medical teams do best when they can talk through all the options—including drugs like entacapone—and pick the path that matches daily goals and changing needs.
If you or someone you know is managing Parkinson’s, it pays to keep up with conversations about what’s new and what fits. Medicine like entacapone isn’t magic, but it can open doors to better days—sometimes, that’s worth everything.
Anyone living with Parkinson’s knows how tough it gets to keep up with daily routines. Entacapone helps by making other Parkinson’s medications last longer in the body. Still, no drug works in isolation. There are side effects that show up in real life, not just on a pharmacy leaflet. Doctors and pharmacists often share lists, but lived experience, and honest talk, fill in the gaps those lists miss.
Digestive issues hit home right away for many people. It isn’t rare to feel the urge to run to the restroom more often. Diarrhea ranks high on the complaint chart. Some people feel nausea that makes it harder to get through meals. These problems may seem small on paper, yet missing a meal or getting dehydrated from stomach trouble throws the whole day out of whack. I have seen people need to temporarily stop Entacapone just to get a break for their gut.
Colored urine comes as a surprise for newcomers. The change to yellow-brown or orange-red shades might startle you, but it’s not dangerous. Still, not everyone gets warned about it, which makes that first experience feel unsettling.
Entacapone works with levodopa to control tremors and stiffness, but sometimes, muscle spasms kick up anyway. Some get dyskinesia—those involuntary jerking or twisting movements nobody wants. It gets worse when medication peaks, making even pouring coffee risky business. Talking to the doctor about adjusting the combo often keeps things manageable. Skipping or stretching out doses on your own just leads to more drama, so medical guidance pays off.
Fatigue follows people on Entacapone. It’s not just feeling tired. It slows thinking, makes multitasking hard, and can put a dent in social plans. Sometimes, confusion or hallucinations show up—especially in older adults. These don’t always get named right away, and that lag in diagnosis can strain relationships. Handwritten notes or a journal can help track changes and show patterns over time, giving doctors something to work with.
Allergic reactions, though rare, still mean business. Swelling, rash, or trouble breathing call for an emergency response. Most people don’t see these, but knowing what to watch for gives some peace of mind. Liver problems sometimes sneak in, showing up as yellowing skin or eyes, dark urine, or right upper belly pain. Routine blood tests matter, even if the symptoms never pop up.
Working closely with a healthcare team beats playing medication roulette alone. Pharmacists keep a sharp eye on drug interactions, which helps when mixing Entacapone with other prescriptions or supplements. Drinking water, keeping meals bland during stomach upsets, and honest updates during appointments all go a long way.
Every side effect brings its own set of challenges. What works for one person may not help someone else, which makes open discussion key. No one knows your body’s quirks better than you, so tracking symptoms and sharing them makes a difference in how much Entacapone helps—or hurts—in daily life.
Entacapone finds a place in the daily routine of people fighting Parkinson’s disease. Living with Parkinson’s means dealing with stiffness, tremors, and movements that sometimes just will not cooperate. This medicine works by helping other drugs, like levodopa, last longer in your system. Many families, including members of my own, have watched the daily grind of Parkinson’s. A missed pill can mean a tricky day. So figuring out how to work entacapone into your life is more than just following a routine. It’s about getting hours of better movement, a little less fatigue, and maybe the chance to do normal things others take for granted.
Doctors typically pair entacapone with every dose of carbidopa/levodopa. From actual conversations with pharmacists and people living with Parkinson’s, they often take one 200 mg tablet of entacapone with each carbidopa/levodopa dose—up to eight times a day. That’s a lot to manage, but skipping can undo hours of good movement. People sometimes cut corners or experiment with their dosing. That’s risky, especially since the brain likes predictable routines. Clarity from doctors really helps here, and a dedicated pill organizer works wonders. Jot down pill times on your phone or on paper and align it with your daily landmarks—like meals, news programs, or set alarms. This creates structure, even on the tough days.
Nausea, diarrhea, and colored urine pop up more often than folks expect. From friends’ experience, noticing bright orange urine early on can cause worry, but it’s harmless. If stomach troubles show up, some find that a snack with the pill makes things smoother. Chasing side effects feels frustrating, yet stopping entacapone cold turkey can spiral movements out of control. I’ve seen people try to “tough out” nausea or tiredness only to end up skipping the very pills meant to help. Open talks with the doctor help. Tweaks in timing or food can make a big difference. Also, sharing honest feedback saves time—it prevents playing phone tag with the clinic because of an avoidable side effect.
Entacapone’s job is to slow the breakdown of levodopa, helping it cross the blood-brain barrier. But it’s not the only player. Other medications and high-protein meals can mess with absorption. In my own family’s experience, eating heavy protein at the same time as levodopa often led to rough afternoons. The studies back this up—protein competes for absorption. Planning meal times and medicine times a couple hours apart kept things steady. Review every medicine you take, not just the ones for Parkinson’s. Over-the-counter decongestants and common cold remedies can trip you up too. Pharmacists can spot risky combos in your list at a glance and save you some trial and error.
Life changes happen—travel, new supplements, unexpected illnesses. Each one pushes your routine off course. I’ve seen friends adjust doses without telling their neurologist, thinking it’s a small tweak. Even half a tablet off can throw symptoms into chaos. Bringing up every change, even if it seems tiny, keeps everyone on the same page. Some clinics offer telehealth check-ins, which reduces the barrier to sharing those questions popping up at midnight. If a side effect starts bugging you, don’t wait for the next scheduled visit. Report it quickly and save yourself needless rough days.
Living with Parkinson’s usually doesn’t mean just taking one pill. Most people with this condition juggle a mix of medications, each aimed at fighting symptoms that can shift from day to day. It’s exhausting trying to keep track, and new treatments always raise a big question: Will it play nice with the ones already in the medicine cabinet?
Entacapone works as an “add-on,” not as the main event. Its job is simple: stretch out the effects of levodopa, the gold-standard Parkinson’s drug. Levodopa often fades before the next dose, sometimes leaving hours where tremors and stiffness burst back in. That’s where Entacapone steps up, blocking a certain enzyme (COMT) so levodopa lasts longer in the body. People don’t take Entacapone by itself; it rides along with each levodopa/carbidopa dose.
Doctors often layer medications, targeting different symptoms with a combo tailored for the individual. Entacapone usually joins the mix alongside levodopa/carbidopa. It doesn’t interfere much with dopamine agonists like pramipexole or MAO-B inhibitors such as rasagiline. Instead, it quietly boosts levodopa’s punch, helping smooth out “off” episodes that interrupt the day.
Researchers have found that Entacapone can reduce “off” time by about one hour each day for people who add it to long-term levodopa treatment. That may not sound massive on paper, but any hour that hands back control matters if you’re struggling with shaky hands or rigid muscles. Still, this comes with a trade-off: levodopa’s longer action brings a higher risk of dyskinesias—those involuntary, sometimes twisting movements that can be just as tough as the original symptoms.
Many drugs raise concerns about dangerous combos, but Entacapone, in my experience, rarely clashes with most other Parkinson’s medicines when taken as directed. Dopamine agonists, anticholinergics, and even amantadine can mix into the regimen without big surprises, as long as a doctor keeps a watchful eye. Still, stomach upset, diarrhea, and darkened urine show up in some folks after starting Entacapone. Liver troubles remain rare, but blood tests help catch problems early if they arise.
Levodopa/Entacapone combinations can lead to confusion, hallucinations, or more dramatic blood pressure drops, especially in older people or those with existing memory problems. Having a neurologist monitor every medication change and dose adjustment becomes a must—not just helpful advice.
Any time a doctor adds Entacapone to the mix, questions about how it fits with current medications deserve careful answers. I’ve seen cases where extra side effects or sudden symptom shifts confused patients, and they weren’t sure if the new drug, a dosage tweak, or their natural disease course caused the change.
The key is communication. Bring a full medication list to every appointment and mention even minor side effects. If something feels off, speak up, because tiny symptoms early on can point to medication overload or interactions. Pharmacists can also spot trouble spots, especially for folks seeing several different specialists.
Entacapone brings extra flexibility to Parkinson’s treatment, allowing longer relief and a bit more freedom. For many, that makes juggling multiple medications worth it. Careful monitoring, clear conversations, and realistic expectations smooth the road a bit, even when living with a disease full of uncertainty.
Entacapone plays a key role for people with Parkinson’s disease by helping keep the effects of levodopa going longer. Many see it as an add-on, often at a moment in treatment when symptoms start sneaking back between regular doses. Still, it’s a powerful drug that comes with real-world concerns. I’ve heard from caregivers and patients about side effects or dose mix-ups, and these stories show how essential it is to stay one step ahead with this prescription.
Drowsiness and diarrhea crop up right away for a lot of patients. Some stories stick in the mind of fatigue that hit hard in the afternoon or a sudden need to rush to the bathroom at work. Those are not mild annoyances—the fatigue makes it risky to drive or run machinery and digestive issues could really hurt quality of life. Muscle cramps, nausea, or urine turning orange might surprise folks, but they’re well documented. The orange urine isn’t harmful, yet it catches people off guard unless a doctor or pharmacist gives a heads-up.
Parkinson’s doesn’t usually show up in young people, so most taking Entacapone have other chronic health concerns too. People with a history of liver disease need to watch out, because Entacapone puts extra stress on that organ. The FDA includes warnings for those with moderate to severe liver issues, and I’ve seen cases where a doctor pulled the plug on Entacapone after bloodwork suggested trouble. Falls pose a big risk in Parkinson’s, and Entacapone can make movements less predictable. Hallucinations and confusion can happen, creeping in with age or after a dose change.
Clear communication works better than any pill reminder app. Patients should let a doctor know right away if confusion, fainting, or severe diarrhea start to happen. Skipping meals to avoid stomach upset or combining Entacapone with other medications without telling a doctor can bring on more problems. Monoamine oxidase inhibitors, certain antidepressants, or even cough and cold medicines can interact badly. Always double-check the medicine cabinet and ask the pharmacist before adding anything new.
Regular follow-ups help spot liver problems before they get serious. In some places, clinics track liver function every few months for anyone on Entacapone—something that’s helped people avoid hospital stays. Missing or doubling up on doses can trigger wild swings in Parkinson’s symptoms. Pill organizers or help from a family member make a difference, especially if memory problems are starting to show. If new symptoms show up suddenly, don’t wait for the next appointment—hop on the phone or visit the provider.
Training pharmacists and nurses to give clear advice, in plain language, could keep more patients safe. Reminders about drinking enough fluids, how to spot side effects, and warning signs for liver trouble should come up every time a patient gets a refill. Support groups share practical strategies, like keeping a diary of symptoms and medication times. In my own experience, that simple act of writing things down takes away a lot of guesswork and stress. Anyone using Entacapone deserves steady care, not just a signature on a prescription.
| Names | |
| Preferred IUPAC name | (E)-2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)prop-2-enamide |
| Other names |
Comtan Entacom Stalevo Comtess |
| Pronunciation | /ɛnˈtækəˌpoʊn/ |
| Identifiers | |
| CAS Number | 130929-57-6 |
| Beilstein Reference | 1446854 |
| ChEBI | CHEBI:6356 |
| ChEMBL | CHEMBL1210 |
| ChemSpider | 54684 |
| DrugBank | DB00494 |
| ECHA InfoCard | The ECHA InfoCard of Entacapone is: **100.121.340** |
| EC Number | 1.97.1.10 |
| Gmelin Reference | 84806 |
| KEGG | D04022 |
| MeSH | D000069835 |
| PubChem CID | 60851 |
| RTECS number | OK GZ5C83729X |
| UNII | UYQ7NOB9U7 |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C14H15N3O5 |
| Molar mass | 305.273 g/mol |
| Appearance | Orange crystalline powder |
| Odor | Odorless |
| Density | 1.4 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 2.6 |
| Vapor pressure | 7.94E-14 mmHg |
| Acidity (pKa) | 9.37 |
| Basicity (pKb) | 10.37 |
| Magnetic susceptibility (χ) | -60.6e-6 cm³/mol |
| Refractive index (nD) | 1.62 |
| Dipole moment | 3.73 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 357.5 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -241.3 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -1804 kJ/mol |
| Pharmacology | |
| ATC code | N04BX02 |
| Hazards | |
| Main hazards | May cause cancer, causes serious eye irritation, may cause respiratory irritation, may cause damage to organs through prolonged or repeated exposure. |
| GHS labelling | GHS07, GHS08, Warning, H302, H332, H373 |
| Pictograms | liver" "time" "tablet" "prescription |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Keep out of reach of children. For oral use only. Use only as directed by a physician. Store at 20° to 25°C (68° to 77°F). Protect from moisture. Do not use if allergic to entacapone or any ingredients in the formulation. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| Flash point | 119.2°C |
| Autoignition temperature | 320 °C |
| Explosive limits | Lower: 0.5 vol%, Upper: 3.9 vol% |
| Lethal dose or concentration | LD50 (rat, oral): > 2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Entacapone: "1,600 mg/kg (rat, oral) |
| PEL (Permissible) | 35 µg/m³ |
| REL (Recommended) | 200 mg |
| Related compounds | |
| Related compounds |
Carbidopa Levodopa Tolcapone Opicapone Selegiline |
